Inflation Reduction Act of 2022 (“IRA”) – Impact on Drug Pricing

groupH has analysed what is known about the Inflation Reduction Act (IRA) of 2022, which constitutes a major legislative effort to address drug pricing and Medicare expenditure. We developed a simple easy-to-use model, which assesses the risk of any of the three parts of the IRA applying to a product that is either already on the market or still in development.

The IRA model has been developed based on primary market research with senior US market access experts and secondary analysis. The model and its associated white paper was first presented during the Fierce Biotech NPP Summit in Boston in October 2023.

Please click here to access the paper.

Please click on the image below to access the model.